Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 16.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 444,142 shares of the life sciences company’s stock after selling 84,324 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.28% of Illumina worth $46,360,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Capital Investment Services of America Inc. grew its stake in shares of Illumina by 1.2% in the second quarter. Capital Investment Services of America Inc. now owns 80,336 shares of the life sciences company’s stock worth $8,385,000 after acquiring an additional 977 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Illumina by 3.6% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock valued at $41,748,000 after buying an additional 13,725 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Illumina by 2,203.6% in the second quarter. Blue Trust Inc. now owns 2,534 shares of the life sciences company’s stock valued at $264,000 after buying an additional 2,424 shares during the last quarter. 180 Wealth Advisors LLC raised its holdings in shares of Illumina by 34.3% in the second quarter. 180 Wealth Advisors LLC now owns 20,786 shares of the life sciences company’s stock valued at $2,170,000 after buying an additional 5,312 shares during the last quarter. Finally, PGGM Investments raised its holdings in shares of Illumina by 80.8% in the second quarter. PGGM Investments now owns 411,362 shares of the life sciences company’s stock valued at $42,938,000 after buying an additional 183,784 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ILMN shares. Daiwa America raised shares of Illumina to a “strong-buy” rating in a report on Friday, August 16th. Piper Sandler reduced their target price on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Citigroup upped their target price on shares of Illumina from $140.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Scotiabank reduced their target price on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a report on Thursday, August 15th. Finally, Barclays raised shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price target for the company in a report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $151.10.

Illumina Stock Down 0.5 %

ILMN traded down $0.65 during trading hours on Wednesday, reaching $131.86. 562,589 shares of the stock traded hands, compared to its average volume of 2,115,260. The firm’s fifty day simple moving average is $115.60 and its two-hundred day simple moving average is $122.08. The company has a market cap of $21.01 billion, a price-to-earnings ratio of -16.26 and a beta of 1.15. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $171.50. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.24. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The firm’s revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period last year, the business earned $0.32 EPS. As a group, analysts forecast that Illumina, Inc. will post 1.5 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.